Efficacy of Prolonged Treatment With Pegylated Interferon (Peg-IFN) and Ribavirin in Thalassemic Patients With Hepatitis C Who Relapsed After Previous Peg-IFN-Based Therapy
| Author | Saleh Sandoughdaran | en |
| Author | Seyed Moayed Alavian | en |
| Author | Heidar Sharafi | en |
| Author | Bita Behnava | en |
| Author | Shima Salimi | en |
| Author | Leila Mehrnoush | en |
| Author | Pegah Karimi Elizee | en |
| Author | Maryam Keshvari | en |
| Issued Date | 2015-01-01 | en |
| Abstract | Background: Most thalassemic patients with chronic hepatitis C virus (HCV) infection do not respond to therapy with pegylated interferon (Peg-IFN) plus ribavirin (RBV) due to hepatic siderosis and RBV dose reduction caused by RBV-induced anemia. Objectives: In the present study, we recruited HCV genotype 1-infected thalassemic patients who had relapsed after a 48-week treatment with Peg-IFN plus RBV in order to evaluate the efficacy of a 72-week regimen of Peg-IFN plus RBV. Patients and Methods: In this retrospective study, 23 thalassemic patients with HCV genotype 1 infection who had prior relapse after treatment with Peg-IFN and RBV for 48 weeks were consecutively enrolled in this study for evaluation of the efficacy of a 72-week treatment regimen. Results: For the 21 included cases, mean age was 29.7 years; 81% were men and 28.6% had cirrhosis. At the end of the treatment, nine (42.9%) patients had an undetectable level of HCV RNA in their sera. However, six months after treatment completion four of these patients relapsed and a sustained virological response (SVR) was found in five (23.8%) patients. Undetectable HCV RNA level at week 4 (P = 0.03) and undetectable HCV RNA level at week 12 (P < 0.01) were found to be predictors of SVR. There was an average 47.9% increase in blood transfusion during therapy and treatment was discontinued for 12 (57.1%) patients prematurely. Conclusions: The present study suggests that thalassemic patients with chronic hepatitis C genotype 1 infection who did not achieve SVR after a course of therapy with Peg-IFN and RBV may benefit from being retreated with a 72-week regimen. | en |
| DOI | https://doi.org/10.5812/hepatmon.23564 | en |
| Keyword | Hepatitis C | en |
| Keyword | peginterferon alfa-2a | en |
| Keyword | Ribavirin | en |
| Keyword | Thalassemia | en |
| Publisher | Brieflands | en |
| Title | Efficacy of Prolonged Treatment With Pegylated Interferon (Peg-IFN) and Ribavirin in Thalassemic Patients With Hepatitis C Who Relapsed After Previous Peg-IFN-Based Therapy | en |
| Type | Research Article | en |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- 15448-pdf.pdf
- Size:
- 56.32 KB
- Format:
- Adobe Portable Document Format
- Description:
- Article/s PDF